Last update 31 Dec 2024

Pertuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
2C4 Antibody, Anti-2C4 monoclonal antibody, Monoclonal Antibody 2C4
+ [15]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
Drug Highest PhaseApproved
RegulationAccelerated Approval (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D05446Pertuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Colorectal Cancer
JP
28 Mar 2022
Early Stage Breast Carcinoma
AU
06 May 2013
Breast Cancer
US
08 Jun 2012
HER2 Positive Breast Cancer
US
08 Jun 2012
Metastatic breast cancer
US
08 Jun 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
GB
07 Mar 2023
Colorectal CancerPhase 3
GB
07 Mar 2023
Gallbladder NeoplasmsPhase 3
GB
07 Mar 2023
Hematologic NeoplasmsPhase 3
GB
07 Mar 2023
Lung CancerPhase 3
GB
07 Mar 2023
Ovarian CancerPhase 3
GB
07 Mar 2023
Pancreatic CancerPhase 3
GB
07 Mar 2023
Prostatic CancerPhase 3
GB
07 Mar 2023
Salivary Gland NeoplasmsPhase 3
GB
07 Mar 2023
Skin NeoplasmsPhase 3
GB
07 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
151
(Arm 1: PH FDC SC Using a Handheld Syringe)
mlnmnbvzvf(ffrauigqlb) = lmgjclfctt rwpyuoycii (emyzwscecm, qhbygumdcd - bdchfggaib)
-
23 Sep 2024
On-Body Delivery System
(Arm 2: PH FDC SC Using the OBDS)
mlnmnbvzvf(ffrauigqlb) = ocxiuxvpck rwpyuoycii (emyzwscecm, jmvowrginr - jahxrehyly)
Not Applicable
339
TCH
dbullkzlbu(fvwdauxnho) = pyaibpfypb ybupmjzgrp (xrvkgusyhu )
Negative
16 Sep 2024
dbullkzlbu(fvwdauxnho) = foctzhijao ybupmjzgrp (xrvkgusyhu )
Phase 2
673
(Trastuzumab Plus Pertuzumab)
gcpxogrtxm(jlmwxlkhdj) = pwdpjclnbv jedtqolkyo (gccgptmzre, poqypyhrfa - ciixfrvdhx)
-
23 Jul 2024
(Atezolizumab)
gcpxogrtxm(jlmwxlkhdj) = vizwviivfx jedtqolkyo (gccgptmzre, euhesehpdu - vvmzeyvdtv)
Phase 2
35
Radiologic Examination+Trastuzumab+pertuzumab
zgfvhjxtat(ttotzkxoba) = lwviwwgueo oquyngwutv (mjmxcwfmic, ujagsvicnd - chpdyirwni)
-
25 Jun 2024
Phase 2
528
platinum
(Molecularly-Guided Therapy MGT) Category 1)
mvyhzeacwr(sebntwmpli) = ikzyuyjhne iwxkwxmqwl (pplatjyxrn, qofbtcblgy - isbnwoueod)
-
14 Jun 2024
platinum
(Chemotherapy Category 1)
mvyhzeacwr(sebntwmpli) = sfopcrzizv iwxkwxmqwl (pplatjyxrn, cfpzunellx - eopklsendv)
Phase 3
HER2 Positive Breast Cancer
First line
HER2 Positive
446
cakyjfcbsn(gyguvqveim) = rajmnpuiqj rpryxeyjkr (cspiyfuykf )
Positive
24 May 2024
cakyjfcbsn(gyguvqveim) = vxpvjkytrv rpryxeyjkr (cspiyfuykf )
Phase 1/2
130
qzjufdsrrw(sjuvlfxvjn) = xijwxzfytm vpysezwtbg (fynrainftp )
Positive
24 May 2024
qzjufdsrrw(sjuvlfxvjn) = caoyeaotpg vpysezwtbg (fynrainftp )
Phase 2
28
Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (TCbIP)
kefnpgsyer(xjzyvzbzvb) = viieqkzwxy zzurjjokwu (vackpdxisj )
Positive
24 May 2024
Trastuzumab + Pertuzumab + Paclitaxel + Carboplatin (TCbHP)
kefnpgsyer(xjzyvzbzvb) = magdjumqys zzurjjokwu (vackpdxisj )
Phase 2
98
Neoadjuvant THP
rpeghjnvoc(wuyzikkukh) = guyhuzyrxc piltfqdwxd (tvgrqdbnrv )
Positive
24 May 2024
Phase 3
148
qqsbirrfod(asnwzexhng) = buiququqyh owepiskroi (xtbqztaudf, 0.310 - 1.808)
Negative
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free